Locus ceruleus degeneration is ubiquitous in Alzheimer's disease: Possible implications for diagnosis and treatment

Neuropathology

Volumn 26, Issue 6, 2006, Pages 528-532

  Haglund, Mattias ^a   Sjöbeck, Martin ^a   Englund, Elisabet ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Leukoaraiosis; Locus coeruleus; Neuropathology; Vascular dementia

Indexed keywords

NORADRENALIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN DEGENERATION; BRAIN DISEASE; BRAIN ISCHEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; ISCHEMIA; LOCUS CERULEUS; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; NORADRENALIN BRAIN LEVEL; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; VASCULAR DISEASE; WHITE MATTER; WHITE MATTER DISEASE;

ADRENERGIC AGONISTS; ALZHEIMER DISEASE; DEMENTIA; HUMANS; LEUKOARAIOSIS; LOCUS COERULEUS; NOREPINEPHRINE; SEVERITY OF ILLNESS INDEX;

EID: 33751270153     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2006.00725.x     Document Type: Article

References (31)

1. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-1239.
2. Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol (Berl) 1983; 61: 101-108.
3. Lyness SA, Zarow C, Chui HC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 2003; 24: 1-23.
4. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003; 60: 337-341.
5. Cohen Z, Molinatti G, Hamel E. Astroglial and vascular interactions of noradrenaline terminals in the rat cerebral cortex. J Cereb Blood Flow Metab 1997; 17: 894-904.
6. Kalaria RN, Harik SI. Increased alpha 2- and beta 2-adrenergic receptors in cerebral microvessels in Alzheimer disease. Neurosci Lett 1989; 106: 233-238.
7. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986; 19: 253-262.
8. Englund E, Brun A, Gustafson L. A white-matter disease in dementia of Alzheimer's type - clinical and neuropathological correlates. Int J Geriatr Psychiatry 1989; 4: 87-102.
9. Londos E, Passant U, Gustafson L, Brun A. Neuropathological correlates to clinically defined dementia with Lewy bodies. Int J Geriatr Psychiatry 2001; 16: 667-679.
10. Hirono N, Kitagaki H, Kazui H, Hashimoto M, Mori E. Impact of white matter changes on clinical manifestation of Alzheimer's disease: a quantitative study. Stroke 2000; 31: 2182-2188.
11. Starkstein SE, Sabe L, Vazquez S et al. Neuropsychological, psychiatric, and cerebral perfusion correlates of leukoaraiosis in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997; 63: 66-73.
12. Mountjoy CQ, Bondareff W. Comparison of counts of neurons in the locus coeruleus made from serial sections and from a single section at the centre of the nucleus. Can J Neurol Sci 1986; 13: 480-482.
13. Brun A, Gustafson L. The longitudinal dementia study: a 25-year perspective on neuropathology, differential diagnosis and treatment. In: Corain B, Iqbal K, Nicolini M, Winblad B, Wisniewski H, Zatta P (eds) Alzheimer's Disease - Advances in Clinical and Basic Research. New York: John Wiley and Sons Ltd, 1993; 3-18.
14. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239-259.
15. Brun A, Englund E. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 1981; 5: 549-564.
16. Mann DM, Yates PO, Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry 1982; 45: 113-119.
17. Englund E, Brun A. White matter changes in dementia of Alzheimer's type: the difference in vulnerability between cell compartments. Histopathology 1990; 16: 433-439.
18. Sjobeck M, Haglund M, Englund E. Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease - a neuropathological study. Int J Geriatr Psychiatry 2005; 20: 919-926.
19. Haglund M, Englund E. Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord 2002; 14: 161-166.
20. Marcyniuk B, Mann DM, Yates PO. The topography of cell loss from locus caeruleus in Alzheimer's disease. J Neurol Sci 1986; 76: 335-345.
21. Bondareff W, Mountjoy CQ, Roth M et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord 1987; 1: 256-262.
22. German DC, Manaye KF, White CL 3rd et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 1992; 32: 667-676.
23. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989; 287: 373-392.
24. Rye D, DeLong MR. Time to focus on the locus. Arch Neurol 2003; 60: 320.
25. Heneka MT, Galea E, Gavriluyk V et al. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci 2002; 22: 2434-2442.
26. Wenk GL, McGann K, Hauss-Wegrzyniak B, Rosi S. The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease. Neuroscience 2003; 121: 719-729.
27. Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry 2002; 51: 407-416.
28. Zweig RM, Ross CA, Hedreen JC et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988; 24: 233-242.
29. Zubenko GS, Moossy J. Major depression in primary dementia. Clinical and neuropathologic correlates. Arch Neurol 1988; 45: 1182-1186.
30. Weller RO, Yow HY, Preston SD, Mazanti I, Nicoll JA. Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer's disease. Ann N Y Acad Sci 2002; 977: 162-168.
31. Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54.